Claims
- 1. A method of treating 5-HT.sub.3 -mediated disorders which comprises administering to subjects suffering from 5-HT.sub.3 -mediated disorders an effective amount of a compound of the formula: ##STR16## a pharmaceutically acceptable acid addition salt form or a stereochemically isomeric form thereof, wherein:
- R.sup.1 and R.sup.2 represent hydrogen;
- n represents 2, 3 or 4;
- R.sup.3 represents hydrogen or methoxy;
- m represents 1 or 2;
- R.sup.4 represents hydrogen, amino or C.sub.1-3 alkylcarbonylamino; and
- R represents hydrogen or halo.
- 2. A method according to claim 1, wherein R.sup.3 represents methoxy and has the cis-configuration.
- 3. A method according to claim 2, wherein the compound is laevo-rotatory.
- 4. A method according to claim 1, wherein the compound is (-)-cis-4-amino-5-chloro-2,3-dihydro-N-�1-�3-�(3,4-dihydro-4-oxo-2-pyrimidinyl)amino!propyl!-3-methoxy-4-piperidinyl!-2,2-dimethyl-7-benzofurancarboxamide or (-)-cis-4-amino-5-chloro-N-�1-�2-�(3,4-dihydro-4-oxo-2-pyrimidinyl)amino!ethyl!-2,3-dihydro-3-methoxy-4-piperidinyl!-2,2-dimethyl-7-benzofurancarboxamide, or a pharmaceutically acceptable acid addition salt form thereof.
- 5. The method of claim 1, wherein the 5-HT.sub.3 mediated disorder is selected from the group consisting of anxiety, psychosis, depression, schizophrenia, cognitive disorders, drug abuse, migraine, emesis and irritable bowel syndrome.
- 6. The method of claim 2, wherein the 5-HT.sub.3 mediated disorder is selected from the group consisting of anxiety, psychosis, depression, schizophrenia, cognitive disorders, drug abuse, migraine, emesis and irritable bowel syndrome.
- 7. The method of claim 3, wherein the 5-HT.sub.3 mediated disorder is selected from the group consisting of anxiety, psychosis, depression, schizophrenia, cognitive disorders, drug abuse, migraine, emesis and irritable bowel syndrome.
- 8. The method of claim 4, wherein the 5-HT.sub.3 mediated disorder is selected from the group consisting of anxiety, psychosis, depression, schizophrenia, cognitive disorders, drug abuse, migraine, emesis and irritable bowel syndrome.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a divisional of application Ser. No. 08/416,914, filed on Jun. 16, 1995, now U.S. Pat. No. 5,674,868, which in turn was the national stage of PCT Application Ser. No. PCT/EP 93/03206, filed Nov. 15, 1993, which claims priority as a continuation-in-part from U.S. application Ser. No. 07/979,013, filed on Nov. 20, 1992.
Foreign Referenced Citations (4)
Number |
Date |
Country |
A-0076530 |
Apr 1983 |
EPX |
A-0309043 |
Mar 1989 |
EPX |
A-0389037 |
Sep 1990 |
EPX |
A-0445862 |
Sep 1991 |
EPX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
416914 |
Jun 1995 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
979013 |
Nov 1992 |
|